FILE PHOTO: Tablets of Avigan , a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. . REUTERS/Issei KatoCamostat, a 35-year old pancreatitis drug made by Osaka-based Ono Pharmaceutical Co, has captured the interest of scientists in Japan and overseas with little fanfare or state assistance.
Interest in Avigan soared in March after a Chinese official said that it appeared to help patients recover from COVID-19, the flu-like infection caused by the coronavirus. It is now the subject of at least 14 clinical trials. Amidst a global rout in stocks, shares in Fujifilm have shot to record highs.
The use of Avigan is decided by doctors and its approval will depend on medical and scientific evaluation in due course, said Fujifilm spokeswoman Kana Matsumoto. After being tested against a range of viruses, Avigan was finally approved in Japan in 2014, but only for emergency use against flu epidemics, and it was licensed in China where it has since gone off patent.
“It’s got a 35-year track record, so it seemed to be a very safe drug,” he said. “I said we’ve got to try it. I’m a physician and we’re desperate for anything we can give to people.”“I’m 100% certain that we needed to start this trial a month ago. And we can have a definitive result in a month.”
Source: Healthcare Press (healthcarepress.net)
Anti -Japan, Anti -Abe Media 🚨 Avigan Don't spread false rumors ! 🚨 AbeShinzo moteging KatsunobuKato1 MofaJapan_jp MofaJapan_en MIC_JAPAN FakeNews FakeNewsMedia Reuters
drug business boomin
Anti-Japan, anti-Abe media Avigan Don't spread false rumors ! AbeShinzo moteging KatsunobuKato1 MofaJapan_jp MofaJapan_en JPN_PMO FakeNews FakeNewsMedia Reuters
Turkish Health system using this drug since march 👍
We'll see how it does.
Let's find out!
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: USATODAY - 🏆 100. / 63 Read more »
Source: trtworld - 🏆 101. / 63 Read more »
Source: TheEconomist - 🏆 6. / 92 Read more »